Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone650-249-9090
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$257.65 million
Profitability
Miscellaneous
Employees975
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Natera (NASDAQ:NTRA) Frequently Asked Questions
What is Natera's stock symbol?
Natera trades on the NASDAQ under the ticker symbol "NTRA."
How were Natera's earnings last quarter?
Natera Inc (NASDAQ:NTRA) issued its quarterly earnings data on Thursday, May, 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.59) by $0.05. The medical research company earned $66.82 million during the quarter, compared to the consensus estimate of $66.40 million. Natera had a negative return on equity of 699.31% and a negative net margin of 49.33%. View Natera's Earnings History.
When is Natera's next earnings date?
What price target have analysts set for NTRA?
7 brokers have issued 1-year target prices for Natera's stock. Their forecasts range from $20.00 to $41.00. On average, they expect Natera's share price to reach $28.8571 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price. View Analyst Price Targets for Natera.
What is the consensus analysts' recommendation for Natera?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.
What are Wall Street analysts saying about Natera stock?
Here are some recent quotes from research analysts about Natera stock:
- 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (5/15/2019)
- 2. Canaccord Genuity analysts commented, "We’re positive on the deal, which provides NTRA with $50M of non-dilutive financing upfront, royalties on future BGI revenues, and further decentralization of its testing OUS. We don’t understand why the stock is not up 10-15%+ on this news; regardless, we view this deal as a material positive and would buy NTRA stock here. Natera is one of our top picks for 2019 and trades at just 2.9x Street ’20 revs (below its peak of ~5x just 7 months ago). We reiterate our $25 PT and turn our focus to NTRA’s Q4 call tomorrow night. The deal. Under the 10-year agreement, BGI will pay Natera $50 million in upfront licensing fees and prepaid royalties in Q1. Natera will also receive ongoing royalty payments. Natera will prepay BGI Genomics $6M for sequencing services related to this partnership." (3/11/2019)
Has Natera been receiving favorable news coverage?
Media headlines about NTRA stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Natera earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Natera.
Are investors shorting Natera?
Natera saw a decline in short interest during the month of May. As of May 31st, there was short interest totalling 2,186,000 shares, a decline of 11.6% from the April 30th total of 2,473,300 shares. Based on an average daily trading volume, of 743,700 shares, the days-to-cover ratio is presently 2.9 days. Approximately 4.6% of the shares of the stock are short sold. View Natera's Current Options Chain.
Who are some of Natera's key competitors?
Some companies that are related to Natera include ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX) and Cancer Genetics (CGIX).
What other stocks do shareholders of Natera own?
Who are Natera's key executives?
Natera's management team includes the folowing people:
- Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
- Mr. Steve Chapman, CEO, Pres & Director (Age 40)
- Mr. Michael Brophy, Chief Financial Officer (Age 39)
- Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
- Mr. Robert A. Schueren, Chief Operating Officer (Age 57)
When did Natera IPO?
(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Who are Natera's major shareholders?
Natera's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (5.20%), Jennison Associates LLC (5.65%), First Manhattan Co. (1.63%), Kornitzer Capital Management Inc. KS (0.81%), Perkins Capital Management Inc. (0.21%) and Tygh Capital Management Inc. (0.17%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.
Which institutional investors are selling Natera stock?
NTRA stock was sold by a variety of institutional investors in the last quarter, including Tygh Capital Management Inc., FMR LLC, Jennison Associates LLC, Spark Investment Management LLC, Meeder Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera.
Which institutional investors are buying Natera stock?
NTRA stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., Kornitzer Capital Management Inc. KS, Perkins Capital Management Inc., AGF Investments Inc., Moody Aldrich Partners LLC, MYDA Advisors LLC, Asymmetry Capital Management L.P. and Dupont Capital Management Corp. View Insider Buying and Selling for Natera.
How do I buy shares of Natera?
Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Natera's stock price today?
One share of NTRA stock can currently be purchased for approximately $26.31.
How big of a company is Natera?
Natera has a market capitalization of $1.83 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.
What is Natera's official website?
How can I contact Natera?
Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]
MarketBeat Community Rating for Natera (NASDAQ NTRA)
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
